Andreas Schwarting

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie, Michelle Petri, Omid Zamani et al. · Arthritis & Rheumatism · 2011 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

William Stohl, Andreas Schwarting, Masato Okada et al. · Arthritis & Rheumatology · 2017 · 417 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Monocyte Chemoattractant Protein 1–Dependent Leukocytic Infiltrates Are Responsible for Autoimmune Disease in Mrl-<i>Faslpr</i> Mice

Greg H. Tesch, Stefanie Maifert, Andreas Schwarting et al. · The Journal of Experimental Medicine · 1999 · 302 citations · Full text

Life Sciences, Immunology, Pathology +17

Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis

Greg H. Tesch, Andreas Schwarting, Koji Kinoshita et al. · Journal of Clinical Investigation · 1999 · 268 citations · Full text

Medicine, Immunology, Pathology +17

The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy

Catharina Whybra, Christoph Kampmann, Frank Krummenauer et al. · Clinical Genetics · 2004 · 267 citations

Life Sciences, Clinical Sciences, Enzymology +10